John Androsavich, PhD, serves as the Global Head and Emerging Science Lead for RNA Medicine at Pfizer, bringing over 15 years of experience in RNA therapeutics. He has previously helped drive early-stage development of mRNA, siRNA, miRNA, and other RNA-based platforms at companies like Translate Bio, RaNA Therapeutics, and Regulus Therapeutics. Androsavich holds a PhD in Chemical Biology from the University of Michigan and a bachelor’s degree in biology from the University of Pittsburgh.